Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 9/20 | 0.64 |
| ▸ | CDYL | Q9Y232 | 8/20 | 0.64 |
| ▸ | CBX7 | O95931 | 8/20 | 0.64 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 7/20 | 0.64 |
| ▸ | KMO | O15229 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CD74 | P04233 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | TSPO | P30536 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074930 | 0.90 | TP53 (0.66) | CDYL2CDYLCBX7CDY1; CDY1BTP53 | |
| SCHEMBL13099998 | 0.86 | L3MBTL1 (0.53) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL16186527 | 0.86 | L3MBTL1 (0.74) | TP53L3MBTL1CD74MIF | |
| SCHEMBL29957877 | 0.84 | KMO (0.76) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL2950965 | 0.84 | KMO (0.76) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL31324857 | 0.84 | CDYL2 (0.63) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL27033665 | 0.84 | CDYL2 (0.63) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL25307601 | 0.84 | L3MBTL1 (0.58) | CDYL2CDYLCBX7CDY1; CDY1BTP53 | |
| SCHEMBL29958210 | 0.83 | CDYL2 (0.69) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL27033393 | 0.83 | CDYL2 (0.69) | CDYL2CDYLCBX7CDY1; CDY1BKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | CDYL2 3216/4885CDYL 4158/4885CBX7 4711/4885 |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | CDYL2 3216/4885CDYL 4158/4885CBX7 4711/4885 |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | UTS2R, PLAUR, FABP3 | CDYL2 2887/4885CDYL 3568/4885CBX7 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.